A randomized phase II trial of two dosage levels of letrozole as third- line hormonal therapy for women with metastatic breast carcinoma

Cancer

Volumn 80, Issue 2, 1997, Pages 218-224

  Ingle, James N ^a   Johnson, Patricia A ^b   Suman, Vera J ^a   Gerstner, James B ^c   Mailliard, James A ^d   Camoriano, John K ^e   Gesme Jr , Dean H ^f   Loprinzi, Charles L ^a   Hatfield, Alan K ^b   Hartmann, Lynn C ^a  

^a MAYO CLINIC   (United States)

^b Carle Cancer Center CCOP   (United States)

^c Illinois Oncol Res Assoc CCOP   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e Scottsdale CCOP   (United States)

^f Cedar Rapids Oncology Project CCOP   (United States)

Author keywords

Breast carcinoma; Hormonal therapy; Letrozole; Metastatic

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; LETROZOLE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; HEARTBURN; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TUMOR GROWTH; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; SURVIVAL RATE; TRIAZOLES;

EID: 0030927955     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P     Document Type: Article

References (18)

1. Iveson TJ, Ahern J, Smith IE. Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer 1993;29A:572-4.
2. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89-94.
3. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
4. Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994;12:2460-70.
5. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-65.
6. Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hersey D, et al. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987;59:779-82.
7. Santen RJ. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Res Treat 1981;1:183-202.
8. Miller WR. Aromatase inhibitors: Where are we now? Br J Cancer 1996;73:415-7.
9. Bhatnagar AS, Häusler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Molec Biol 1990;37:1021-7.
10. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-70.
11. Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, et al. Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-8.
12. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987;43:81-93.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:547-81.
14. Howell A, Mackintosh J, Jones M, Bedford J, Wagstaff J, Sellwood RA. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
15. Sedlacek SM. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 1988; 15:3-13.
16. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
17. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA). Proc Am Soc Clin Oncol 1996; 15:100.
18. Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:202-8.